Tarek Nafee is a Cardiology physician. OpenAlex indexes 73 publications with 580 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 W 13 Mile Rd
Royal Oak, MI 480736712
Telephone
248-898-5000Provider last certified this registry record 19 Sept 2025.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20257 payments
- Boston Scientific CorporationProgram year20257 payments
- Cook IncorporatedProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.7%Statin66.7%Atorvastatin Calcium100%Part D<11 patientsMetabolism & gastrointestinal
33.3%SGLT2 inhibitor33.3%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Optimal Timing for Complete Revascularization in Acute Myocardial Infarction
Cardiovascular Drugs and Therapy
2025 - ROUTINE USE OF CEREBRAL EMBOLIC PROTECTION DEVICE DURING TRANSCATHETER AORTIC VALVE REPLACEMENT: WHAT DOES THE DATA SUPPORT? AN UPDATED META-ANALYSIS
Journal of the American College of Cardiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”